EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Lepu Biopharma Co's enterprise value is HK$8,522.3 Mil.
Lepu Biopharma Co's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 was HK$393.9 Mil. Therefore, Lepu Biopharma Co's EV-to-Revenue for today is 21.64.
The historical rank and industry rank for Lepu Biopharma Co's EV-to-Revenue or its related term are showing as below:
HKSE:02157'
s EV-to-Revenue Range Over the Past 10 Years
Min: 11.06 Med: 28.34 Max: 715.65
Current: 20.6
During the past 6 years, the highest EV-to-Revenue of Lepu Biopharma Co was 715.65. The lowest was 11.06. And the median was 28.34.
HKSE:02157's EV-to-Revenue is ranked worse than 69.61% of 997
companies
in the Biotechnology industry
Industry Median: 7.39
vs HKSE:02157: 20.60
As of today (2025-06-03), Lepu Biopharma Co's stock price is HK$4.75.
Lepu Biopharma Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was HK$0.23. Therefore, Lepu Biopharma Co's PS Ratio for today is 20.47.
Lepu Biopharma Co EV-to-Revenue Historical Data
The historical data trend for Lepu Biopharma Co's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Lepu Biopharma Co's EV-to-Revenue
For the Biotechnology subindustry, Lepu Biopharma Co's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lepu Biopharma Co's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lepu Biopharma Co's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Lepu Biopharma Co's EV-to-Revenue falls into.
Lepu Biopharma Co's current Enterprise Value is HK$8,522.3 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Lepu Biopharma Co's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 was HK$393.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lepu Biopharma Co (HKSE:02157) EV-to-Revenue Explanation
Lepu Biopharma Co's share price for today is HK$4.75.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2024 was HK$0.23.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lepu Biopharma Co EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Lepu Biopharma Co's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Lepu Biopharma Co Ltd is a biopharmaceutical company focusing on oncology therapeutics and has one operating segment. The Group is principally engaged in the sales of pharmaceutical products and the research and development of new drugs. The majority operating entity of the Group is domiciled in Mainland China. The company has established an integrated end-to-end platform across drug discovery, clinical development, CMC, and GMP-compliant manufacturing, encompassing all critical functions of the biopharmaceutical value chain. The company generates the majority of its revenue from the Sale of pharmaceutical products. The company also generates a small portion of its revenue from Licensing income.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:02157 has been successfully added to your 